Stock HNSPF HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Hansoh Pharmaceutical Group Company Limited Stock OTC Markets

Equities

HNSPF

KYG549581067

Pharmaceuticals

Delayed OTC Markets
Other stock markets
 03:54:35 2024-03-20 pm EDT 		5-day change 1st Jan Change
1.88 USD +19.75% Intraday chart for Hansoh Pharmaceutical Group Company Limited -.--% +2.73%
Apr. 30 Hansoh Pharmaceutical’s 2023 Profit Up 27% MT
Apr. 29 Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 11.82B 1.63B Sales 2025 * 12.5B 1.73B Capitalization 98.04B 13.56B
Net income 2024 * 3.74B 517M Net income 2025 * 3.75B 519M EV / Sales 2024 * 6.5 x
Net cash position 2024 * 21.23B 2.94B Net cash position 2025 * 23.86B 3.3B EV / Sales 2025 * 5.94 x
P/E ratio 2024 *
25.7 x
P/E ratio 2025 *
25.9 x
Employees 9,123
Yield 2024 *
0.93%
Yield 2025 *
0.97%
Free-Float 18.24%
More Fundamentals * Assessed data

Chart Hansoh Pharmaceutical Group Company Limited

Dynamic Chart

Latest news about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical’s 2023 Profit Up 27% MT
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 CI
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug MT
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer CI
Hansoh Pharmaceutical Group Company Limited Recommends Final Dividend, Payable on July 17, 2024 CI
Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nomura Downgrades Hansoh Pharmaceutical to Neutral From Buy, Adjusts Price Target to HK$15.03 From HK$13.01 MT
Hansoh Pharmaceutical Gets Nod to Trial Nephropathy Treatment Capsules MT
Hansoh Pharmaceutical Buys Back 3 Million Shares MT
Fed, China Property Outlooks Roil Asian Stock Markets MT
Hansoh Secures Chinese Nod For Clinical Trial Of Anti-Diabetes Drug MT
China Outlook, Tech Rally Roils Asian Stock Markets MT
Hansoh Pharmaceutical Units Gets Clinical Trial Notice in China for Schizophrenia Treatment MT
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets CI
Federal Reserve Outlook Mutes Asian Stock Markets MT
More news

Analyst Recommendations on Hansoh Pharmaceutical Group Company Limited

Nomura Downgrades Hansoh Pharmaceutical to Neutral From Buy, Adjusts Price Target to HK$15.03 From HK$13.01 MT
Rising Interest Rates Blunt Asian Stock Markets MT
Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$13.01 From HK$19.49, Keeps at Buy MT
Fitch US Debt Downgrade Undercuts Asian Stock Markets MT
China Economic Prospects, Exchange Rates Churn Asian Stock Markets MT
More recommendations

Press releases Hansoh Pharmaceutical Group Company Limited

2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference AQ
Hansoh Pharmaceutical Group Co., Ltd. - The 24th China Patent Awards Ceremony was held, and Hansoh Pharma's Ametinib patent was awarded the China Patent Gold Award AQ
Hansoh Pharmaceutical's Saint Relais is the first batch to be shipped nationwide, bringing a safe and long-lasting new option to CKD patients with renal anemia AQ
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China AQ
KiOmed Pharma and Hansoh Pharma Announce License Agreement for KioMedinevsone in China's Mainland, Macau and Taiwan AQ
More press releases

News in other languages on Hansoh Pharmaceutical Group Company Limited

Las acciones de Hong Kong suben un 0,8%; las esperanzas de estímulo de China animan el ánimo -- Market Talk
Las acciones de Hong Kong terminan planas tras una sesión volátil -- Market Talk
Las acciones de Hong Kong terminan a la baja en un clima de aversión al riesgo -- Market Talk
La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las expectativas -- Market Talk
Las acciones de Hong Kong caen un 1,4%, lideradas por el sector tecnológico -- Market Talk
More news

Quotes and Performance

1 day+19.75%
3 months+19.75%
6 months+2.73%
Current year+2.73%
More quotes

Highs and lows

Current year
1.50
Extreme 1.5
1.88
1 year
1.50
Extreme 1.5
1.88
3 years
1.50
Extreme 1.5
1.88
5 years
1.50
Extreme 1.5
1.88
10 years
1.50
Extreme 1.5
1.88
More quotes

Managers and Directors - Hansoh Pharmaceutical Group Company Limited

Managers TitleAgeSince
Hui Juan Zhong CEO
 Chief Executive Officer 63 15-12-01
Sheng Li Zhong SEC
 Corporate Secretary 56 -
Members of the board TitleAgeSince
Guo Qiang Lin BRD
 Director/Board Member 81 19-05-30
Sheung Wai Chan BRD
 Director/Board Member 70 19-06-13
Dong Tao Yang BRD
 Director/Board Member 67 -
More insiders

Company Profile

Hansoh Pharmaceutical Group Company Limited specializes in the development, manufacture and marketing of pharmaceutical products for the treatment of tumor, infectious, metabolic and autoimmune diseases. Net sales break down by revenue source as follows: - sales of pharmaceutical products (99.1%); - sales of research and development services (0.9%).
Sector
Pharmaceuticals
Calendar
2024-08-28 - Q2 2024 Earnings Release (Projected)
Related indices
HONG KONG HANG SENG
More about the company

Income Statement Evolution

More financial data

Ratings for Hansoh Pharmaceutical Group Company Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
16.5 CNY
Average target price
17.71 CNY
Spread / Average Target
+7.36%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.22% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.57% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.09% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.18% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.42% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.68% 240B
NOVARTIS AG Stock Novartis AG
+9.92% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.63% 203B
AMGEN INC. Stock Amgen Inc.
+7.24% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3692 Stock
  4. HNSPF Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW